US Physical Therapy Inc
NYSE:USPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
US Physical Therapy Inc
NYSE:USPH
|
US |
Intrinsic Value
The intrinsic value of US Physical Therapy Inc (USPH) under the Base Case is 70.41 USD per share.
Compared with the current market price of 85.93 USD, the stock appears
Overvalued by 18% .
The intrinsic value is calculated using the DCF method. The model assumes revenue grows about 8% a year over the next five years, below its five-year pace of 13%. If revenue grew at its five-year pace of 13%, the estimate would be about $115.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
Revenue & Expenses Breakdown
US Physical Therapy Inc
Earnings Waterfall
US Physical Therapy Inc
The intrinsic value for US Physical Therapy Inc (USPH) under the Base Case is 70.41 USD.
Compared with the current market price of 85.93 USD, the stock appears Overvalued by 18% .